[A25-109] Daratumumab (smouldering multiple myeloma) – Benefit assessment according to §35a Social Code Book V
Last updated 17.11.2025
Project no.:
A25-109
Commission:
Commission awarded on 18.08.2025 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Indication:
Adult patients with smouldering multiple myeloma who are at high risk of developing multiple myeloma
Result of dossier assessment:
Added benefit not proven
Note:
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
DOI:
https://doi.org/10.60584/A25-109